These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Suitable examination intervals for hemodialysis patients with secondary hyperparathyroidism treated with maxacalcitol].
    Author: Yamada Y, Kumafuji M, Sodeyama T, Suzawa T, Momose M, Tokoo M.
    Journal: Clin Calcium; 2005 Sep; 15 Suppl 1():144-7. PubMed ID: 16272647.
    Abstract:
    Five patients with secondary hyperparathyroidism undergoing chronic hemodialysis, whose level of intact-PTH was less than 500 pg/mL, were treated with maxacalcitol for 16 weeks. The levels of serum intact-PTH, corrected calcium, phosphorous, ALP and BAP were measured every 2 weeks, and we investigated the suitable examination intervals to evaluate parathyroid function in these patients. Intact-PTH decreased significantly after 6 weeks, and thereafter corrected serum calcium level increased. From these results it is necessary to put emphasis to the time before 8 weeks in the measurement of intact-PTH, and on the other hand, after 8 weeks in the measurement of corrected serum calcium. ALP showed no significant change during the administration period. As a bone metabolic marker, BAP is more useful, and its measurement is enough for every 2 months. In conclusion, suitable examination intervals during the period of maxacalcitol treatment might not be adapted to the recommendation in the K/DOQI guideline 8B.2.
    [Abstract] [Full Text] [Related] [New Search]